系统性红斑狼疮女性合并激素避孕药使用与禁忌证分析
本研究基于SLICC注册队列,纳入927例18-45岁女性SLE患者,评估复方激素避孕药(CHC)在有或无禁忌证者中的使用率及相关因素。结果显示CHC使用率仅8%,且55%的使用发生在存在至少一种可能禁忌证的情况下。CHC使用率远低于普通人群估计的>35%。
要点
- SLE女性CHC使用率低(8%),远低于普通人群(>35%)。
- 超过半数CHC使用者存在至少一种可能禁忌证。
- 最常见禁忌证为抗磷脂抗体(52%)、高血压(34%)和先兆偏头痛(22%)。
核心结论
- SLE女性CHC使用率低,且多数使用者存在至少一种可能禁忌证。
研究设计与样本
- 观察性队列研究,纳入SLICC注册中发病≤15个月的18-45岁绝经前SLE女性,2000-2017年每年评估。
主要发现
- 共927例女性贡献6315次访视,其中3811次(60%)存在至少一种可能禁忌证。
- 512次访视(8%)使用CHC,其中281次(55%)存在至少一种可能禁忌证。
- 有禁忌证者CHC使用率为7%(95% CI 7, 8),无禁忌证者为9%(95% CI 8, 10)。
关键数值与推荐
- WHO第3或4类禁忌证包括高血压和抗磷脂抗体(aPL)等,高疾病活动(SLEDAI>12或泼尼松>0.5 mg/kg/天)视为相对禁忌证。
- 最常见禁忌证:aPL(52%)、高血压(34%)、先兆偏头痛(22%)。
临床怎么用
- 临床处方CHC前应系统评估SLE患者是否存在WHO禁忌证及高疾病活动。
- 对存在禁忌证者应避免或谨慎使用CHC,并考虑替代避孕方式。
局限性
- 可能存在未测量的因素(如患者偏好)影响CHC使用。
- 需进一步研究明确CHC暴露相关的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications. METHODS: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication. RESULTS: A total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)]. CONCLUSION: CHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.
引用
- Mendel A, Bernatsky S, Pineau CA, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019. PMID: 30753683. doi:10.1093/rheumatology/kez014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。